Thalidomide

Generic Name: Thalidomide

Brand Names: Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₀N_₂O_₄

CAS Number: 50-35-1

Unique Ingredient Identifier: 4Z8R6ORS6L

Background: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...

Indication: Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

Associated Conditions: Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma

Associated Therapies: -

Clinical Trials

Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma

Phase 2

Terminated

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2023-01-09

Lead Sponsor: Rush University Medical Center

Target Recruit Count: 5

Registration Number: NCT00014443

Locations: 🇺🇸
Rush Cancer Institute at Rush University Medical Center, Chicago, Illinois, United States

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-04

Lead Sponsor: Nuvance Health

Registration Number: NCT00046826

Locations: 🇺🇸
Whittingham Cancer Center at Norwalk Hospital, Norwalk, Connecticut, United States
🇺🇸
Carl and Dorothy Bennett Cancer Center at Stamford Hospital, Stamford, Connecticut, United States

Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2003-01-27

Last Posted Date: 2019-10-17

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT00049374

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
St. Vincent's Comprehensive Cancer Center - Manhattan, New York, New York, United States

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Phase 2

Completed

Conditions: Recurrent Uterine Corpus Sarcoma
Uterine Corpus Leiomyosarcoma

Interventions: Drug: Thalidomide
Other: Laboratory Biomarker Analysis

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00025220

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Biological: recombinant interferon alfa
Drug: thalidomide

First Posted Date: 2003-01-27

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 38

Registration Number: NCT00006006

Locations: 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer

Phase 2

Withdrawn

Conditions: Kidney Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-11

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT00025519

Thalidomide in Treating Patients With Gynecologic Sarcomas

Phase 2

Completed

Conditions: Endometrial Cancer
Sarcoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-21

Lead Sponsor: New York University Cancer Institute

Registration Number: NCT00006005

Locations: 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

and more 7 locations

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Phase 1

Completed

Conditions: Intraocular Melanoma
Melanoma (Skin)

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00005815

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00016224

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Phase 2

Completed

Conditions: Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Lung Cancer
Neoplastic Syndrome

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00027638

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy